Murae Organisor Ltd
Incorporated in 2012, Earum Pharmaceuticals Ltd manufactures and trades in pharma products[1]
- Market Cap ₹ 156 Cr.
- Current Price ₹ 1.68
- High / Low ₹ 2.72 / 1.03
- Stock P/E 33.2
- Book Value ₹ 2.85
- Dividend Yield 0.00 %
- ROCE 0.79 %
- ROE 0.13 %
- Face Value ₹ 2.00
Pros
- Stock is trading at 0.59 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -45.0% over past five years.
- Company has a low return on equity of 6.02% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 1,543 days.
- Working capital days have increased from 2,490 days to 6,342 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 9m | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 0 | 9 | 19 | 23 | 35 | 51 | 55 | 41 | 21 | 14 | 3 | 340 | |
0 | 0 | 9 | 18 | 23 | 34 | 47 | 54 | 49 | 25 | 13 | 4 | 333 | |
Operating Profit | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 1 | -8 | -4 | 1 | -1 | 6 |
OPM % | 2% | 3% | 2% | 4% | 7% | 2% | -19% | -21% | 7% | -44% | 2% | ||
0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 9 | 8 | 2 | 2 | 0 | |
Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit before tax | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 0 | 3 | 3 | 0 | 6 |
Tax % | 31% | 44% | 33% | 27% | 27% | 26% | 25% | 28% | 29% | 29% | |||
0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 0 | 2 | 2 | 0 | 5 | |
EPS in Rs | 0.20 | 0.32 | 0.46 | 0.83 | 0.04 | 0.00 | 0.05 | 0.05 | 0.00 | 0.04 | |||
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -45% |
3 Years: | -60% |
TTM: | 8246% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -50% |
3 Years: | -18% |
TTM: | 654% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | -15% |
3 Years: | -32% |
1 Year: | -27% |
Return on Equity | |
---|---|
10 Years: | 9% |
5 Years: | 6% |
3 Years: | 6% |
Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.01 | 0.01 | 0.01 | 0.11 | 0.11 | 0.31 | 0.31 | 6 | 6 | 12 | 12 | 49 | 139 |
Reserves | 0 | 0 | 1 | 1 | 1 | 5 | 6 | 8 | 8 | 4 | 6 | 6 | 126 |
0 | 0 | 1 | 2 | 2 | 7 | 10 | 9 | 11 | 9 | 9 | 0 | 260 | |
0 | 0 | 3 | 6 | 7 | 7 | 8 | 12 | 2 | 3 | 1 | 64 | 24 | |
Total Liabilities | 0 | 0 | 5 | 9 | 11 | 20 | 23 | 36 | 28 | 29 | 29 | 120 | 548 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
0 | 0 | 5 | 9 | 11 | 19 | 23 | 32 | 27 | 28 | 28 | 120 | 548 | |
Total Assets | 0 | 0 | 5 | 9 | 11 | 20 | 23 | 36 | 28 | 29 | 29 | 120 | 548 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 0 | -2 | -0 | 0 | -7 | -0 | -3 | -7 | 3 | 0 | -16 | |
0 | 0 | -0 | -0 | -0 | -0 | -0 | -3 | 3 | 0 | 0 | -0 | |
0 | 0 | 2 | 1 | -0 | 7 | 1 | 7 | 3 | -3 | -0 | 28 | |
Net Cash Flow | 0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | -1 | -0 | -0 | 12 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 125 | 87 | 56 | 111 | 78 | 112 | 95 | 261 | 217 | 1,543 | ||
Inventory Days | 71 | 78 | 108 | 91 | 86 | 97 | 122 | 179 | 392 | 1,439 | ||
Days Payable | 113 | 107 | 83 | 77 | 54 | 83 | 10 | 18 | -25 | 7 | ||
Cash Conversion Cycle | 82 | 58 | 82 | 125 | 111 | 126 | 207 | 422 | 635 | 2,975 | ||
Working Capital Days | 81 | 54 | 58 | 116 | 98 | 126 | 222 | 431 | 698 | 6,342 | ||
ROCE % | 0% | 22% | 21% | 22% | 25% | 24% | 17% | 4% | 12% | 12% | 1% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
20 Feb - Resignation of CFO Brijeshkumar Vaghasiya effective February 20, 2025.
-
Integrated Filing (Financial)
14 Feb - Integrated financial filing for Q3 and nine months ended December 2024.
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E., Thursday, 13Th February, 2025
13 Feb - Approval of split of equity shares from Rs. 2 to Re. 1.
-
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations
And Disclosure Requirements) Regulations, 2015
7 Feb - Board meeting to discuss bonus shares and share subdivision.
-
Rumour verification - Regulation 30(11)
31 Jan - Clarification on unauthorized stock recommendations and media claims.
Business Overview:[1]
Company is in the pharmaceutical business handling marketing, trading and distribution of a wide range of pharmaceutical formulation products, of which 120 products are marketed by company under its own brand, and their manufacturing is outsourced to third parties. Apart from this, company also trades in active pharmaceutical ingredients